+1 (202) 780-3397
Anti-Hemolytic Liposomal Drug
2nd International Conferences on Nanotechnology & Chemistry
April 06-07, 2022 | Webinar
Nina Ivanova
Institute of Dermatology and Venereology of Academy of National Medical Science of Ukraine, Kharkov
Scientific Tracks Abstracts : J Pharm Chem Chem Sci
Abstract:
A lot of diseases are connected with hemolysis: hemolytic disease of new-born infants, paroxysmal nocturnal hemoglobinuria, malaria, some medicines also cause hemolysis. In addition, the coronavirus COVID- 19 lowers the amount of hemoglobin due to damage to the erythrocyte membrane. The association of autoimmune hemolytic anemia during Covid-19 infection was described [1]. Known prophylactic treatment of pregnant women with Rhesus conflict for the prevention of hemolytic disease of the newborn. But this drug can cause allergic reactions, sometimes accompanied by anaphylactic shock. Therefore, the development of a non-toxic antihemolytic drug capable of inhibiting hemolysis is an urgent task. In the study of polar negatively charged lipids we found a unique property of some mixtures of lipids inhibit and prevent hemolysis. As a result of these studies, we have developed a liposomal anti-hemolytic drug. The antihemolytic preparation are negatively charged the liposomes with original lipid’s structure on the basis of natural negatively charge lipids. The antihemolytic preparation has been developed for treatment of diseases connected with immune hemolysis: for treatment hemolytic disease of newborns and for inhibition immune hemolysis, caused hemoglobinuria paroxysmalis nocturna. In addition, these liposomes prevented and inhibited non-specific hemolysis caused by the action of some medicine, including antimalarial drugs such as quinine, antibiotics. 1. Researches of liposomal antihemolytic preparation have been carried out in vivo and in vitro. For check of biological activity of preparations for treatment hemolytic disease of newborns we used models of animals with induced hemolytic disease. The hemolytic disease of newborns has been simulated on experimental animals (rabbits, rams) by introduction of the fatal doze of antibodies against erythrocytes. The experimental animals were observed within 2 weeks under the certification received from the Committee on Bioethics and Deontology. The liposomes were obtained by evaporating the lipids in the rotary vacuum evaporator (Switzerland) and were suspended in sterile buffered saline. The liposomes prepared in the extruder EmulsiFlex–C5 (Canada “Avestin”). As much as possible positive therapeutic effect in vivo has been reached: 100 % of animals with induced hemolytic disease were healthy after one injections of our liposomal antihemolytic preparation. All animals of control group with induced hemolytic disease without the preparation were lost. We discovered that the liposomes interacts with the erythrocytes membrane to make them more stable against haemolysis and inactivates antibodies. Based on these studies, the technology of the sterile antihemolytic drug was developed for the treatment of hemolytic disease of the newborn (1% dispersion of liposomes with particle’s size f 140 nm). 2. Studies were also carried out in the laboratory of hemostasis pathology of the Central Institute of Hematology and Blood Transfusion to assess the effect of these liposomes on the intensity of erythrocyte decay in patients with severe hemolytic anemia - paroxysmal nocturnal Hemoglobinuria. The addition of liposomal antihemolytic preparation to the blood in vitro of patients with paroxysmal nocturnal hemoglobinuria prevented of erythrocytes lysis. 3. In addition, the possibility of inhibiting hemolysis caused by the action of certain drugs used to treat sexually transmitted infections and skin diseases has been investigated.As damaging agent were used the following drugs: cefaclor (cephalosporin antibiotic), metronidazole, benzylpenicillin. The experiments were held on the blood of volunteers, patients with various types of dermatoses, including allergies to medicines. Hemolysis test of red blood cells were assayed on spectrophotometer at 418 nm wavelength. Liposomes have been added (in different concentration) to blood of patients, the medicines causing hemolysis have simultaneously been added. After incubation 1 hour at temperature 36,6 °C determined the degree of hemolysis in view of optical density of liposomes. Determined that: - While adding to the blood of patients treated by antibiotic Cefaclor of antihemolytic preparation hemolysis of erythrocytes decreased (from 15% to 0%); In the inhibition of donor erythrocytes hemolysis caused by the action of metronidazole and benzylpenicillin in vitro, similar results were obtained.
Biography:
Dr. Nina Ivanova, Ph.D. She completed Ph.D. from the State University Thin Chemical Technologies 1985. The speciality: bioorganic chemistry, chemistry of natural and physiologically active substances. After that worked for 22 years as the head of the lipid laboratory. Since 2007 I have been working as the leading researcher of the immunology and molecular genetics laboratory, SE Institute of dermatology and venerology of National Medical Science of Ukraine”. She has 160 publications and 30 patents. Her work: developing of the liposomal preparations for the treatment of Alzheimer‘s disease, hemolytic diseases, syphilis, anthelmintics in parasitology, antiinfluenzal vaccine, antimycotics
PDF HTML